REFERENCES
- Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: A meta-analytical review. Addiction 2006; 101(4):491–503. [INFOTRIEVE], [CSA]
- Jaffe JH. Do antagonists have a role in the treatment of opioid dependence? Addiction 2006; 101(4):468–469. [CSA]
- Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997; 14(6):529–534. [INFOTRIEVE], [CSA], [CROSSREF]
- Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343(18):1290–1297. [INFOTRIEVE], [CSA], [CROSSREF]
- Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004; 3:CD002207. [INFOTRIEVE], [CSA]
- Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol Clin Exp Res 2001; 25(9):1335–1341. [INFOTRIEVE], [CSA], [CROSSREF]
- Wikler A. Conditioning factors in opiate addiction and relapse. In Narcotics. Wilner DM, Kassebaum GG, eds. New York: McGraw-Hill, Inc., 1965; 85–100.
- Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. Behavioral naltrexone therapy: An integrated treatment for opiate dependence. J Subst Abuse Treat 2002; 23(4):351–360. [INFOTRIEVE], [CSA], [CROSSREF]
- Galanter M. Network therapy for addiction: A model for office practice. Am J Psychiatry 1993; 150(1):28–36. [INFOTRIEVE], [CSA]
- Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York: Guilford Press, 2002, 428.
- Hunt GM, Azrin NH. A community-reinforcement approach to alcoholism. Behav Res Ther 1973; 11(1):91–104. [INFOTRIEVE], [CSA], [CROSSREF]
- Meyers RJ, Smith JE. Clinical Guide to Alcohol Treatment: The Community Reinforcement Approach. 1st ed. New York: Guilford Press, 1995.
- Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994; 51(12):989–997. [CSA]
- Carroll KM, Nuro KR, O'Malley SS. Compliance Enhancement: a manual for the clinical management of drug-dependent patients; Yale University School of Medicine, CT, Psychotherapy Development Center, Department of Psychiatry, 1999., [CSA]
- Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: A randomized trial. JAMA 2005; 294(8):903–913. [INFOTRIEVE], [CSA], [CROSSREF]
- Stine SM, Kosten TR. Use of drug combinations in treatment of opioid withdrawal. J Clin Psychopharmacol 1992; 12(3):203–209. [INFOTRIEVE], [CSA], [CROSSREF]
- Dubbert PM, King A, Rapp SR, Brief D, Martin JE, Lake M. Riboflavin as a tracer of medication compliance. J Behav Med 1985; 8(3):287–299. [INFOTRIEVE], [CSA], [CROSSREF]
- Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. 1st ed. New York: Guilford Press, 1991, 348.
- Marlott GA, Gordon JR. Relapse Prevention and Maintenance Strategies in the Treatment of Addictive Behaviors. New York: Guilford Press, 1985.
- Silverman K, Chutuape MA, Bigelow GE, Stitzer ML. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: Effects of reinforcement magnitude. Psychopharmacology (Berl). 1999; 146(2):128–138. [CSA], [CROSSREF]
- Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: Effects on drug use of methadone maintenance patients. J Consult Clin Psychol 1992; 60(6):927–934. [INFOTRIEVE], [CSA], [CROSSREF]
- Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, Fenwick JW. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991; 148(9):1218–1224. [INFOTRIEVE], [CSA]
- Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150(5):763–769. [INFOTRIEVE], [CSA]
- Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51(7):568–576. [INFOTRIEVE], [CSA]
- Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 1998; 66(5):811–824. [INFOTRIEVE], [CSA], [CROSSREF]
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research, 2002., [CSA]
- McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992; 9(3):199–213. [INFOTRIEVE], [CSA], [CROSSREF]
- Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62. [INFOTRIEVE], [CSA]
- Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13(3):293–308. [INFOTRIEVE], [CSA]
- Sobell MB, Maisto SA, Sobell LC, Cooper AM, Cooper TC, Sanders B. Developing a prototype for evaluating alcohol treatment effectiveness. In Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. Sobell LC, Sobell MB, Ward E. eds. New York: Permagon Press, 1980.
- Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999; 54(2):127–135. [INFOTRIEVE], [CSA], [CROSSREF]
- Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001; 58(8):755–761. [INFOTRIEVE], [CSA], [CROSSREF]
- Carroll KM, Sinha R, Nich C, Babuscio T, Rounsaville BJ. Contingency management to enhance naltrexone treatment of opioid dependence: A randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol 2002; 10(1):54–63. [INFOTRIEVE], [CSA], [CROSSREF]
- Fals-Stewart W, O'Farrell TJ. Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol 2003; 71(3):432–442. [INFOTRIEVE], [CSA], [CROSSREF]
- Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997; 45(1–2):131–134. [INFOTRIEVE], [CSA], [CROSSREF]
- Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP, TheNEPODResearchGroup. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004; 99(4):450–460. [INFOTRIEVE], [CSA], [CROSSREF]
- Ritter AJ. Naltrexone in the treatment of heroin dependence: Relationship with depression and risk of overdose. Aust N Z J Psychiatry 2002; 36(2):224–228. [INFOTRIEVE], [CSA], [CROSSREF]
- Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002; 159(4):351–360. [CSA], [CROSSREF]
- Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63(2):210–218. [INFOTRIEVE], [CSA], [CROSSREF]
- Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. VivitrexStudyGroup. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293(13):1617–1625. [INFOTRIEVE], [CSA], [CROSSREF]
- Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003; 8(2):211–217. [INFOTRIEVE], [CSA], [CROSSREF]
- Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79(3):351–357. [INFOTRIEVE], [CSA], [CROSSREF]